In another important step for Exact Sciences, the Madison, WI-based company said today that the Centers for Medicare & Medicaid Services (CMS) will reimburse the use of its (Read more...)
Take four years of work, some complicated scientific and medical research, and condense into 25-second nuggets that you will present before judges and a lively crowd as you (Read more...)
It was a beautiful, brisk fall day last Tuesday at the deCordova Sculpture Park and Museum in Lincoln, MA. Xconomy took over the entire museum (Read more...)
Thousand Oaks, CA-based Amgen said Monday it has halted all use of its experimental antibody therapy rilotumumab, which it took on more than a decade ago with the (Read more...)
It wasn’t too long ago that Prosensa Holding was kicked to the curb by Wall Street investors. Following a failed Phase 3 trial for its Duchenne Muscular Dystrophy (Read more...)
To catch a glimpse of new technology that could help farmers get more from plants in the soil, look to the sky.
Aerial drones might be more commonly (Read more...)
Among the slew of challenges in drug development, there’s this: how can you efficiently get a big molecule, like a protein or nucleic acid, into a cell?
That (Read more...)
The role of the trillions of microbes in the human body is poorly understood—and that’s even more so in plants. A growing number of companies are trying to (Read more...)
For more than a decade researchers have been unleashing a deluge of information about the role of genes in disease, based on automated sequencing of DNA. Genetic tests (Read more...)
San Diego-based BioNano Genomics, which has taken a fundamentally different approach to analyzing the genome, says today it has closed on $53 million in Series C financing (Read more...)
N30 Pharmaceuticals, a Boulder-based pharmaceutical company developing drugs for cystic fibrosis, announced yesterday it has raised a $30 million mezzanine financing round. N30 Pharma will use the (Read more...)
The Fred Hutchinson Cancer Research Center in Seattle has unveiled D. Gary Gilliland as its new president and director. He steps to the helm with a strong tailwind, (Read more...)
Shares of Clovis Oncology dropped 10 percent this morning following the release of interim results for the ongoing trial of the company’s drug for lung cancer patients.
Analysts (Read more...)
The next time Gilead Sciences (NASDAQ: GILD) has a drug ready for an all-important Food and Drug Administration review, it can jump the line.
That’s because Gilead, (Read more...)
Houston biotech firm Bellicum Pharmaceuticals has filed for a $115 million IPO.
The company is developing immunotherapies that allow the suppression or activation of cells administered to patients (Read more...)